Timeline of COVID-19 Campus Actions
The University of Maryland took a number of actions related to campus operations in response to the COVID-19 pandemic. While these actions served to ensure the health and safety of our faculty. Staff, and students, the measures also impacted the ability of faculty to engage in their expected responsibilities. When combined with global COVID-19 pandemic health and safety measures, the impact on faculty activities was immediate, and in many cases, the impacts are ongoing even after the lifting of various restrictions.
To guide your evaluation of our tenure and/or promotion candidates and to provide context, the below timeline highlights critical measures and restrictions that the University of Maryland imposed between March 2020 and June 2021.
| Research Phase / Restriction | Definition | Effective Dates |
|---|---|---|
| Phase 0 | Severe research restrictions. Defined as one person per lab to prepare research spaces for reopening. In addition, human subjects, clinical, and community-based research were suspended. | March 21, 2020 - June 7, 2020 |
| Travel | All University-sponsored travel suspended. | March 9, 2020 - July 23, 2020 |
| Phase I | Limited presence. Defined as 25% of all researchers are back in their campus labs. Limited resumption of human subjects/clinical research. Community-based research suspension continued. | June 8, 2020-August 23, 2020 |
| Travel | Limited essential University-funded domestic travel permitted with approval by Dean or Vice President. University-funded International travel prohibited. | July 24, 2020-May 12, 2021 |
| Phase II | Intermediate presence. Defined as up to 50% of researchers to return to their campus labs. Human subjects/clinical research on a case-by-case basis. Community-based research suspension continued. | August 24, 2020-April 4, 2021 |
| Travel | University-funded domestic travel permitted. Exception to University-funded international travel prohibition with approval from Dean or Vice President. | May 13, 2021-present |
| Phase III | Full resumption. Defined as up to 75% of researchers to return to their campus labs. Human subjects/clinical research on a case-by-case basis. Community-based research suspension continued. | April 5, 2021-May 27, 2021 |
| 100% lab occupancy. Human subjects/clinical research enabled fully with COVID health and safety requirements in place. Community-based research suspension lifted. | May 28, 2021-present |